Peter and I participated in a research project that developed a simple blood test called Pleximmune @plexision. It predicts the likelihood of rejection in pediatric patients by analyzing the unique immune chemistry of both the child and the donor. The test also helps doctors determine exactly how much immunosuppression a child needs to keep rejection at bay. Our family knows firsthand how valuable this early warning system truly is.
Personalized Medicine For Better Health
-
25, Jun 2026
-
21, Apr 2025
SAN FRANCISCO — August, 2025.
-
23, Oct 2022
Plexision, a biotechnology company, is offering the first blood test panel ca
-
26, May 2021
An exploratory study reported on May 23, 2021, in MedRxiv described changes i
-
6, May 2021
In transplant recipients on chronic immunosuppression, COVID-19 infection is
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- - Assess disease risk for several immunological disorders.
- - Predict the success of a drug for a specific patient.
- - Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA